Lung Cancer

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.

Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.

Racial minorities with limited-stage small cell lung cancer, including African American and Asian patients, were found to have more favorable survival outcomes compared with White patients, which suggests that race is associated with survival in this disease.

Drs Brown and Husain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

During the past 12 months, the treatment landscape for patients with non–small cell lung cancer has expanded dramatically with FDA approvals of the first drugs directed at KRAS G12C and EGFR exon 20 mutations as well as continued progress in developing new therapies for subsets of patients with other molecularly targetable alterations and with PD-L1–high disease.

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

Chad V. Pecot, MD, discusses the growth of actionable targets in lung cancer.

Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .

Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.

Patients with non-small cell lung cancer harboring KRAS mutations have been an underserved population with few treatment options, specifically those with G12V mutations.

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.

Future projections regarding the role of novel I-O therapies as frontline treatment for patients with metastatic non–small cell lung cancer.

The Chinese National Medical Products Administration has approved durvalumab plus standard-of-care platinum chemotherapy, in the form of etoposide plus either carboplatin or cisplatin, as a frontline treatment option for patients with extensive-stage small cell lung cancer.

Tycel Jovelle Phillips, MD, reviews current therapy options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and how he selects among these options and highlights some potential new therapies.

The highly differentiated mechanism of action of plinabulin, an investigational, first-in-class, selective immunomodulating microtubule binding agent, has positioned the drug as a potential preventive treatment for chemotherapy-induced neutropenia, as well as an anticancer agent in non–small cell lung cancer.

The combination of atezolizumab plus bevacizumab elicited encouraging, durable responses in patients with advanced malignant peritoneal mesothelioma, irrespective of tumor mutational burden and PD-L1 expression status.

Among a plethora of novel immunotherapeutic and targeted agents, the treatment landscapes for small cell lung cancer and non–small cell lung cancer have witnessed a rapid expansion that has led to improved survival and quality of life for patients, including a wider range of patients who harbor molecular abnormalities.

Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.

Amivantamab ushers in a new era of targeted treatment for patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations.

Recommendations for managing immune-related adverse events associated with checkpoint inhibitors used to treat stage IV non–small cell lung cancer.